In high-risk patients with pulmonary arterial hypertension, Merck ’s fusion protein therapeutic Winrevair reduced the ...

This infographic highlights the key advantages of CHO cells and the technologies that are pushing the boundaries of cell ...

The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...

Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) functional class (FC) 3 or 4 at ...

The result puts Scholar Rock out in front of a small group of drugmakers developing myostatin-targeting drugs for SMA, alongside Biohaven's recombinant protein drug taldefegrobep alfa – in the ...

A previously unknown protein in a family of bacteria found in soil and the human gut microbiome has been discovered—which ...

The Global Recombinant Chemicals Market is valued at approximately USD 2.9 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 7.8% over the forecast period 2024-2032.

FRANKLIN, TN, USA I March 31, 2025 I Lynch Regenerative Medicine, LLC., (LRM) announced today that it has acquired exclusive rights to REGRANEX® gel and ...